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Thrombophilia
Menno V. Huisman, MD, and Frits Rosendaal, MD
Thrombophilia is now considered a multicausal disease, with
an interplay of acquired and genetic risk factors. Recent
studies have shown that patients with the 20210 A prothrom-
bin mutation display remarkably similar characteristics
compared with patients with Factor V Leiden mutation. It is
evident that neither the Factor V Leiden mutation nor the
20210 A prothrombin mutation is a major risk factor for
myocardial infarction or stroke, unless accompanied by other
classical risk factors, including diabetes mellitus, hypertension
and smoking. Finally, the homozygous forrVi of the thermolabile
methylenetetrahydrofolate reductase gene, although leading to
elevated homocysteine levels, seems not to represent a
genetic risk factor for venous thrombosis. CurrOpm Hematoi 1999,
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Venous thrombosis is a frequently occurring disorder
with an estimated annual incidence of around one per
1000 people per year. The term "thrombophilia" is used
to describe a tendency to develop thrombosis on the
basis of inherited or acquired disorders of blood coagula-
tion and fibrinolysis that increase the risk of thrombosis.
Examples of acquired risk factors include immobiliza-
tion, surgery, trauma, plaster casts, lupus anticoagulants,
and malignancy. Besides, pregnancy and the use of
estrogens have been shown to be associated with venous
thrombosis. The entity of thrombophilia was first intro-
duced in 1956 by Jordan and Nandor f f [1], who
descr ibed 43 fami ly members with a th rombot ic
tendency. In 1965, Egeberg et al. [Z] reported the first
family with antithrombin deficiency and thrombotic
tendency. Since then, multiple defects in the genes of
anticoagulant proteins have been identified. Until 1994,
the prevalence of then-known genetic defects with an
established risk of venous thrombosis, ie, antithrombin,
protein C and protein S, among patients with venous
thrombosis was rather low. In a large series of 2132
pat ients with documented venous thrombosis, the
prevalence of one of these deficiencies was 10.9% [3]. In
one case-control study [4] in 277 consecutive patients
with documented venous thrombosis, the combined
prevalence was 8.3%, compared with 2.2% in the 138
control subjects. In a third study [5] in 474 unselected
patients, the prevalence was 6.8% versus 3.0% among
474 control subjects. Since 1994, at least four abnormali-
ties have been described that are far more commonly
encountered: activated protein C (APC) resistance
caused by Factor V Leiden; the 20210 G to A Variation
in the prothrombin gene (20210 A prothrombin muta-
tion); high levels of Factor VIII; and hyperhomocys-
teinemia. This article reviews recent studies performed
in patients with Factor V Leiden, the 20210 A prothrom-
bin mutation, and hyperhomocysteinemia.
Factor V Leiden
In physiologic circumstances, thrombin, when bound on
the endothelial surface, activates protein C into APC.
Activated protein C then inactivates the cofactors Factor
Va and Factor Villa. In 1993, a resistance to this APC was
described in patients [6]; it was subsequently shown that
in more than 95% of cases, this is caused by a single point
mutation in the Factor V molecule (FV R506Q), which is
called Factor V Leiden [7,8]. In the general population,
the allelic frequency varies from 1% to 8% among whites
[9], with" very high prevalences occurring in South
Sweden (up to 15 percent) and the Middle Fast. Factor V
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is extremely rare to absent in nonwhite people [10]. In
patients with venous thrombosis, Factor V Leiden has
been found in 20 (unselected patients) up to 50%
(selected patients) [11]. The risk for venous thrombosis in
heterozygous carriers of the Factor V Leiden has been
estimated to be increased four- to eightfold.
In a large, comparative, retrospective cohort study in 723
first- and second-degree relatives of 150 index patients,
Martinelli et al. [12] found relative risks of 8.1 (95% confi-
dence interval (CI) 3.4 to 19.6) for antithrombin, 7.3 (95%
CI 2.9 to 18.4) for protein G, and 8.5 (95% CI 3.5 to 20.8)
for protein S deficiency, whereas the risk ratio for Factor
V Leiden in this study was 2.2 (95% CI 1.1 to 4.7). The
risk of thrombosis for subjects with Factor V Leiden in
this study thus seemed lower than the risk for subjects
with all three other coagulation defects. However, in the
Leiden Thrombophilia Study [13], which had a case-
control design, a relative risk of 7 was found for patients
with heterozygous Factor V Leiden mutation, versus a
relative risk for protein C, protein S, and antithrombin of
6.5, 1.5, and 5.0 respectively.
Whether Factor V Leiden is a risk factor for thrombosis
in older patients was investigated in 79 patients with a
mean age of 83 years who had had at least one proven
episode of venous thromboembolism. The prevalence of
Factor V Leiden mutation was 11.4%; only one patient
had an antithrombin deficiency [14]. The researchers
concluded from this study that even at a higher age,
Factor V Leiden is a frequently occurring risk factor.
A new Factor V mutation associated with resistance to
protein C (Factor V Cambridge, Arg306—>Thr) was
found in one patient with venous thrombosis and
confirmed APC resistance in the absence of the
common R506 Q mutation [15]. Subsequent screening
of 585 patients with venous thrombosis, and 226 blood
donors, did not reveal any other patient with this muta-
tion, so the authors concluded that the Thr306 mutation
is not a common polymorphism but a rare cause of APC
resistance.
The 20210 A prothrombin mutation
This prothrombotic mutation involves a guanine-to-
adenine transition at nucleotide 20210 in the untrans-
lated region of the gene encoding prothrombin. In a
population-based patient control study (the Leiden
Thrombophilia Study) [16], heterozygosity for the
2021OA allele was found more frequently among consec-
utive patients with a first deep-vein thrombosis (6.2%)
than in the control subjects (2.2%). The relative risk for
thrombosis associated with the prothrombin 20210A
allele was 2.8 (95% CI 1.4 to 5.6). Heterozygous carriers
had significantly higher levels of prothrombin (1.32
U/m L) than noncarriers (1.05 U/mL). Thus, it is likely
that the prothrombin 20210A allele acts through the
elevated plasma prothrombin levels.
Geographie distribution
In a compara t ive s tudy [17·], the 20210 G to A
prothrombin variant was proved to follow a somewhat
different geographic pattern from the Factor V Leiden
mutation. After combining data from 11 centers in nine
countries, the Overall prevalence was calculated. Among
5527 people, 111 heterozygous carriers of the 20210 A
allele had been found. The prevalence estimates varied
from 0.7 to 4.0 between the centers, and the overall
prevalence estimate was 2.0 percent (95% CI 1.4-6.2%).
Interestingly, in southern Europe the prevalence was
3.0 percent (95% CI 2.3 to 3.7%), whereas in northern
Europe, the prevalence was 1.7% (95% CI 1.3 to 2.2%).
The 20210 A allele was very rare in people of Asian and
black desceni.
Homozygous G20210A prothrombin mutation
In reviewing data from three case studies [18-20], it
appears that carriers of a homozygous 20210 A mutation,
ie, carriers with homozygous Factor V Leiden mutation,
do not have äs severe thrombotic diathesis äs those with
homozygous protein C or protein S deficiency (in which
purpura fulminans is often encountered) or homozygous
type I antithrombin deficiency (which is thought to be
incompatible with life) [21]. Most homozygous carriers
have experienced early, spontaneous, sometimes severe
thrombot ic disease. Interestingly, one 72-year-old
a s y m p t o m a t i c pa t ien t had homozygous 20210 A
prothrombin and underwent two episodes of major
surgery without prophylactic treatment [20].
Cerebral vein thrombosis
Cerebral vein thrombosis is a rare manifestation of
thrombotic disease with a high mortality rate, estimated
to be 5% to 30%. It has been found to be associated with
Factor V Leiden, ,the use of oral contraceptives, and
pregnancy. The relation between the 20210 A prothrom-
bin gene mutation and cerebral-vein thrombosis, äs well
äs the potential interaction with the use of oral contra-
ceptives, has been studied in 40 unrelated patients with
cerebral-vein thrombosis who were compared with 120
healthy control subjects [22·]. The prevalence of the
prothrombin mutation was significantly higher in the
patients than in the healthy control subjects, 20% and
3% respectively (odds ratio, 10.2; 95% CI 2.3 to 10). The
use of oral contraceptives was more frequent in patients
(96%) than in control subjects (32%; odds ratio, 22.1;
95% CI 5.9 to 84.2). For women who both had the
prothrombin gene mutation and used oral contraception,
the odds ratio for cerebral-vein thrombosis was 149.3
(95% CI 31.0 to 711.0). These results are in line with
data of another study [23], in which the prevalence of
Factor V Leiden was 14% among 36 patients with cere-
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bral vein thrombosis, versus an expected prevalence in
the general population of 4% to 5%. The age-adjusted
odds ratio for venous thrombosis in oral contraceptives
users was 13 (95% CI 5 to 37) in this study [23]. In a
third study [24], 45 patients with cerebral vein thrombo-
sis were compared with 354 healthy blood donors and
131 patients with either acute ischemic stroke or tran-
sient ischemic attack. A total of four patients with cere-
bral-vein thrombosis (8.9%) had the prothrombin gene
mutation, versus eight of 354 (2.3%) in the healthy
controls. In contrast, three of 131 (2.3%) subjects (2.3%)
with an acute cerebrovascular accident or transient
ischmemic attack had the mutation, indicating that the
2021OA prothrombin mutation plays only a minor role in
arterial ischemic cerebral events.
'*,
Risk of recurrent venous thromboembolism
One of the main reasons to investigate both a patient
after an episode of venous thrombosis and his family
members for inherited disorders of blood coagulation is
to give specific therapeutic and prophylactic recommen-
dations on the basis of laboratory findings. Although
many articles appear on the prevalence of inherited risk
factors and their related relative risk in patients with
established venous and arterial thrombosis, few studies
exist that have assessed the incidence of recurrent
venous thromboembolism after stopping oral anticoagu-
lant treatment in patients with a genetic defect who
have had venous thrombosis, because initially, these
patients were mostly put on lifelong anticoagulant treat-
ment. Second, no studies have yet assessed the inci-
dence of a first thromboembolic event in asymptomatic
but affected family members, nor are studies available
that have compared duration or intensity of oral antico-
agulant treatment in patients with a history of venous
thrombosis and an inherited defect.
Referring to the first type of study, Eichinger et al. [25]
studied the risk of early recurrent venous thromboem-
bolism in a follow-up study of 492 patients with a history
of venous thromboembolism. The 20210 A allele was
present in 42 patients (8.5%). Recurrent venous throm-
boembolism had to be confirmed by objective tests.
Duration of anticoagulant therapy had to be at least
three months. Mean follow-up time was 26 months, plus
or minus 18 months, for the 20210 A positive group, and
25 -'onths, plus or minus 18 months, for the 20210 A
negative group. Three patients (7%) with the 20210 A
allele underwent a recurrent thromboembolic event,
versus 54 patients (12%) without the mutation. The
cumulative probability of recurrence did not differ
between patients with or without the 20210 A mutation.
It was concluded that the risk of early recurrence venous
thromboembolism was not higher in heterozygous carri-
ers of the 20210 A mutation than in patients without the
mutation. In this study [25], however, the exact duration
of oral ant icoagulat ion was not predetermined and
varied greatly among the patients. The results of this
study are corroborated by a very recent study by Kearon
et al. [26], who randomly assigned patients with a first
episode of idiopathic thromboembolism after three
months of oral ant icoagula t ion to e i ther cont inue
warfarin therapy (international normalized ratio 2.0-3.0)
or to receive placebo for 24 months. After an average
follow-up period of 10 months, the rate of recurrent
thromboembolic events among 83 patients who received
warfarin for three months was 27.4% per patient-year
(17 patients had a recurrence), versus 1.3% per patient-
year (one of the 79 patients had a recurrent event)
among those who received prolonged oral anticoagulant
treatment (95% risk reduction). Three patients (3.8%) in
the war fa r in group had nonfa ta l major b leed ing ,
compared with none of those assigned to the placebo
group, a statistically significant difference. The preva-
lence of Factor V Leiden mutation was 26% and the
prevalence of the 20210 A prothrombin mutation was
5%. It appeared that in this study [26], these mutations
were not associated with recurrent venous thromboem-
bolism. In comparison, researchers in two earlier studies
evaluated the risk of recurrent venous thromboem-
bolism in patients with Factor V Leiden. Ridker et al.
[27] foilowed 77 patients with idiopathic venous throm-
boembolism. Seven patients among 63 genetically unaf-
fected people had a recurrence, an incidence of 11.1%,
whereas four recurrences developed among 14 heterozy-
gotes for Factor V Leiden, for an incidence of 28.6%. In
the second study [28], the recurrence rate of venous
thromboembolism among 112 Factor V Leiden patients
was 9.9% after a median observation time of 19.3
months, and 9.7% in 268 patients without Factor V
Leiden mutation.
Thus, it remains uncertain whether Factor V Leiden or
the 20210 A prothrombin mutation confer a greatly
increased risk for recurrent venous thromboembolism
after a period of oral anticoagulation of 3 to 6 months. A
clear need exists for prospective s tudies wherein
patients with thromboembolism and Factor V Leiden or
20210 A prothrombin mutation are foilowed for a fixed
duration of prolonged, then possibly less intensive, anti-
coagulant treatment. Such studies are now ei ther
planned or already started [29].
Factor V Leiden, the prothrombin 20210 A
allele, and arterial thrombosis
Although the association between venous thrombosis
and Factor V Leiden or 20210 A prothrombin mutation is
well demonstrated, most data on the risk of arterial
thrombotic events indicate that the carriership of these
gene defects does not confer a major risk for arterial
disease·." In a large study of 560 middle-aged men with a
first myocardial infarction before age 70, the prevalence
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of the 20210 A variant of the prothrombin gene was
1.8%, whereas in the control group this prevalence was
1.2% [30]. This indicates that the risk of myocardial
infarction was increased by 50%, but the 95% confidence
interval was wide and not incompatible with the absence
of a risk excess (odds ratio 0.6 to 3.8). For carriership of
Factor V Leiden, the risk of myocardial infarction was
increased by 40%; the 95% confidence limits ranged
from 0.8 to 2.2. These data suggest a modest increase in
risk for the prothrombin mutation, which was substan-
tially increased if a gene defect coincided with one of the
major cardiovascular risk factors like obesity, smoking,
hypertension, or diabetes mellitus, with resulting odds
ratios varying between 3 and 6. Importantly, in the
absence of the coagulation defects, these risks then
exceeded those of the single effects. These results
confirm two other studies performed in young women
ages 18 to 44 years, in whom much higher risks were
found (two- to fourfold increase for gene defect carriers)
and for whom the relative risk of carriers of either Factor
V Leiden or the 20210 A prothrombin allele was espe-
cially high if another major cardiovascular risk factor was
present (increased 20- to 40-fold) [31,32]. All three
studies may be interpreted äs examples of interactions
between atherosclerotic risk factors and hemostatic
defects, which appear to be more relevant in younger
patients. This is further underlined by a population
based study of 5201 men and women over age 65 who
were followed for a mean time of 3.4 years. Among 373
incident cases of myocardial infarction, angina, stroke, or
transient ischmemic attack, the Factor V Leiden muta-
tion was not a risk factor for any of these events [33].
Finally, to assess whether either Factor V Leiden muta-
tion or the 20210 A prothrombin allele increase the risk
of stroke in young women, in a case-control study [34],
106 women ages 18 to 44 years who all had undergone a
first stroke were compared with 391 control subjects who
had not undergone stroke. It was concluded that for
young women who had undergone stroke, neither Factor
V Leiden nor the 20210 A prothrombin mutation is an
important risk factor.
Combined 20210 A prothrombin mutation
and Factor V Leiden mutation
Since Factor V Leiden has been discovered äs the most
common inherited defect of blood coagulation, it has
become apparent that venous thrombosis often should
be considered äs being caused by multiple factors. Many
inherited and acquired risk factors could cosegregate
with Factor V Leiden, and this could possibly lead to
thrombosis both becoming manifest in younger patients
and having increased severity. For protein G, protein S,
and antithrombin, a higher risk of thrombosis has been
demonstrated in three studies [35-37],
To assess how often the 20210 A prothrombin mutation
is co- inher i ted with Factor V Leiden muta t ion ,
Ehrenfort et al. [38] studied 200 carriers of Factor V
mutation, 150 of whom had had a thrombosis before age
45, and 200 healthy control subjects, in all of whom FII
genotyping was performed. The 20210 A allele was
found in four of the 200 healthy controls, a prevalence of
2%. Among the 50 asymptomatic people with Factor V
Leiden, the prevalence was 4%. In contrast, of the 115
patients with heterozygous Factor V Leiden mutation,
14 (12.2%) had the 20210A allele, whereas five of the 35
patients (14%) with homozygous Factor V Leiden also
had a 20210 A allele. In the presence of the 20210 A
allele, the risk for thrombosis occurring at a young age
was increased threefold in patients with heterozygosity
for Factor V Leiden, which itself was shown to increase
the risk for thrombosis around fourfold. The median age
at which patients underwent a first thrombosis was 27
years for those with double defects, 33 years for those
with the 20210 A allele, and 29 years for those with
Factor V Leiden. In another study [39] of 332 people
from 53 families with APC resistance, both the 20210 A
prothrombin and Factor V Leiden mutations were
tested. Of 29 persons with Factor V Leiden mutation,
three (10%) also had the 20210 A prothrombin mutation,
which was higher than the 1.8% (five of 282) found in
the healthy control subjects. Both reports differ from a
large study by Alhenc-Gelas et al. [40], who did not find
any 20210 A prothrombin mutation among 151 subjects
with heterozygous Factor V Leiden mutation. An expla-
nation of the disparate findings might be that in the
latter study [40], most subjects (66 of 151) were asymp-
tomatic and possibly older than the subjects in the
former two studies. It is concluded that, like Factor V
Leiden, the 20210 A p ro th rombin m u t a t i o n may
increase the risk of thrombosis in people affected with
protein G, protein S, or antithrombin deficiency.
Hyperhomocysteinemia
Mild hyperhomocysteinemia has been shown to be a
risk factor for venous thrombosis and may be caused by
genetic and environmental factors. Den Heijer et al.
[41·] performed a meta-analysis of ten case-control
studies on venous thrombosis and found a pooled esti-
mate of the odds ratio of 2.5 (95% CI 1.8-3.5) for a
fasting homocysteine level above the 95th percentile.
The most common genetic variant that results in hyper-
homocysteinemia is caused by a Substitution in methyl-
enetetrahydrofolate reductase (MTHFR), the enzyme
that converts 5,10-methylenetetra-hydrofolate to 5-
methyltetra-hydrofolate, the carbon donor in homocys-
teine remethylation by methionine synthase [42]. The
resultant 677T variant is thermolabile and has reduced
activity in people who are homozygous or heterozygous
for this mutation. Debate has occurred äs to whether
this variant is a risk factor for thrombosis. Initial reports
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showed this variant to be a risk factor, especially in
combination with Factor V Leiden mutation, whereas
other reports did not support the hypothesis. In three
reports, investigators have studied the risk for venous
thrombosis of the 677T variant either with or without
the Factor V Leiden mutation or the 20210 A prothrom-
bin muta t ion . K l u i j t m a n s et al. [43] s tud ied the
frequency of the homozygous 677C —> T mutant geno-
type of the MTHFR gene in 471 patients with deep-vein
thrombosis and 474 healthy controls and its interaction
with Factor V Leiden mutation. Homozygosity for the
677T variant was observed in 10% of the patients and
9.9% of the control subjects. In addition, no modified
risk of the genotype was observed in carriers of Factor V
Leiden. In the second study [44], using a somehow
similar approach but with the 202LO A prothrombin
mutation äs a second variable, 558 unselected patients
with venous thromboembolism were compared with 500
control subjects. The odds ratio for the MTHFR C677T
variant heterozygosity and homozygosity were 1.07 (95%
CI 0.84 to 1.36) and 0.71 (95% CI 0.48 to 1.03), respec-
tively. In patients with the Factor V Leiden or 20210 A
prothrombin mutation, no increase in risk caused by the
MTHFR 677T variant was seen. In the third study,
Margaglione et al. [45] studied 277 consecutive patients
with confirmed deep-vein thrombosis and 431 healthy
subjects. The homozygous 677T variant was more
frequent in patients than in control subjects (25.6%
versus 18.1%, respectively; P = 0.016). The risk of
thrombosis among carriers of this genotype was signifi-
cantly increased (odds ratio 1.6; 95% CI 1.1 to 2.3). The
estimated risk associated with the homozygous 677T
variant was 2.0 (95% CI 1.3 to 3.1) for those patients
with predisposing risk factors, inc luding Factor V
Leiden, prothrombin mutation, or acquired risk factors,
but the estimated risk stayed significant at 1.7 (95% CI
1.2 to 2.6) after adjustment for gender, Factor V Leiden,
and 20210 A prothrombin mutation. These authors [45]
concluded, in contrast to the previous two studies, that
the homozygous MTHFR 677T genotype is an inde-
pendent risk factor for venous thrombosis.
Several conclusions related to homocysteinemia and
venous thrombosis can be drawn. First, the relation
between mild homocysteinemia and venous thrombosis
has been clearly established. Second, most studies have
not found an association of homozygosity of the thermo-
labile MTHFR and increased risk for venous thrombo-
sis. Third, published studies on the interaction between
Factor V Leiden or the 20210 A prothrombin mutation
and the thermolabile MTHFR are controversial. Third,
although in one study a clear interaction between hyper-
homocysteinemia an Factor V Leiden was observed
(when compared with men with neither abnormality,
those affected by both disorders had a 10 fold increase
in risk of venous thromboembolism) [46] in another
study the combined effect was smaller than for Factor V
Leiden alone [47] and it is thus yet unclear whether
such an interaction really exists. Finally, clinicians must
realize that Intervention studies with pharmacological
lowermg of homocysteine levels are cur ren t ly be
performed and should give definitive answers on the
relevance of homocysteine lowering towards reduction
of thrombotic risk.
Conclusions
Thrombophilia can now be considered a multicausal
disease in which genetic and acquired risk factors interact
with each other [48]. Among the common genetic abnor-
malities of coagulation, numerous studies have been
performed in the previous year m patients with the
recently discovered 20210 A prothrombin mutation. From
these studies, the concept has emerged that the clinical
features of patients with a 20210 A prothrombin mutation
are remarkably comparable with those of patients with
Factor V Leiden mutation. In spite of a slight shift
towards the southern European population, the 20210 A
prothrombin mutation is prevalent in the white popula-
tion and very rare in people of black and Asian descent.
The homozygous prothrombin mutation does not lead to
the severe thrombotic disease äs does protein C defi-
ciency or a n t i t h r o m b i n def iciency, a l though most
homozygous carriers experience early and sometimes
severe thrombotic episodes. It is uncertain whether the
20210 A pro th rombin muta t ion confers a risk for
increased recurrent venous thromboembolism. As for
Factor V Leiden, no major role seems to exist for the
prothrombin mutation in relation to arterial thrombotic
complications, unless patients have other, more classical
risk factors for arterial ischemic disease. Finally, if a
combination of Factor V Leiden and 20210 A prothrom-
bin mutation occurs, it may lead to higher risk for throm-
bosis. With respect to hyperhomocysteinemia, it is now
evident that although homozygosity for the 677T poly-
morphism of MTHFR is associated with increased homo-
cysteine levels, this homozygous mutation by itself is not
an independent risk factor for deep vein thrombosis,
regardless of the Factor V Leiden genotype.
References and recommended reading
Papers of particular interest, published withm the annual penod of review,
have been highlighted äs
• Of special interest
·· Of outstandmg interest
1 Jordan FLJ, Nandorff A The familiai tendency in thromboembolic disease.
Acta Med Scand 1956, 156-267-275
2 Egeberg O inhented antithrombin deficiency causing thrombophilia.
Thromb Diathesis Haemorrhagica 1965, 13-516-530
3 Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J Laboratory evaluation
and clinical charactenstics of 2132 consecutive unselected patients with
venous thromboembolism1 results of the Spanish multicentnc study on
thrombophilia Thromb Haemost 1997, 77.444-451
4 Heyboer H, Brandjes DPM, Bueller HR, Sturk A, ten Cate JW Deficiencies
of coatjulation-inhibitmg and fibnnolytic proteins in outpatients with deep-
vein thrombosis N Engl J Med 1990, 323Ί 512-1516
296 Hemostasis and thrombosis
5 Koster T, Rosendaal FR, Briet E, van der Meer FJM, Colly LP, Tnenekens
PH, et al Protein C deficiency m a controlled senes of unselected outpa
tients an mfrequent but clear nsk factor for venous thrombosis Blood
1995,85 2756-2761
6 Dahlbaeck B, Carlsson M, Svenson PJ Familial thrombophilia due to a
previously unrecognised mechamsm charactensed by poor anticoagulation
response to activated protein C prediction of a cofactor to activated
protein C Proc Natl Acad Sei U S A 1993, 90 1004-1008
7 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven R, de Ronde
H et al Mutation m blood coagulation Factor V associated with resistance
to activated protein C Nature 1994, 369 64-67
8 Zoller B, Svensson P, He X, Dahlback B Identification of the same Factor
V gene mutation m 47 out of 50 thrombosis prone families with mhented
resistance to activated protein C J Clm Invest 1994, 94 2521-2524
9 Rees DC, Cox M, Clegg JB World distnbution of Factor V Leiden Lancet
1995,346 1133-1134
10 De Stefano V, Chiusolo P, Paciaroni K, Leone G Epidemiology of Factor V
Leiden clmical implications Semin Thromb Hemost 1998, 24 367-379
11 Koster T, Rosendaal FRR, de Ronde H Briet E Venous thrombosis due to
poor anticoagulant response to activated protein C Leiden Thrombophilia
Study Lancet 1993, 342 1503-1506
12 Martinelli l, Mannucci PM, De Stefano V, Taioli E, Rossi V, Crosti F, et al
Different risks of thrombosis m four coagulation defects associated with mher-
ited thrombophilias a study m 150 families Blood 1998 922353-2358
13 van der Meer FJM, Koster T, Vandenbroucke JP Briet E, Rosendaal FR The
Leiden Thrombophilia Study (LETS) Thromb Haemost 1997, 78 631 -635
14 Andre E Siguret V, Alhenc Gelas M, Samt Jean O, Gaussem P Venous
thrombosis m older people prevalence of the factor v gene mutation q506
J Am Genatr Soc 1998, 46 1545-1549
15 Williamson D, Brown K, Luddington R, Baglm C Baglm T Factor V
Cambridge a new mutation (Arg 306 —> Thr) associated with resistance to
activated protein C Blood 1998, 91 1140-1144
16 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM A common genetic van
ation m the 3 untranslated region of the prothrombin gene is associated
with elevated plasma prothrombin levels and an mcrease m venous throm-
bosis Blood 1996, 88 3698-3703
17 Rosendaal FR Doggen CJ, Zivelm A, Arruda VR, Aiach M, Siscovick DS, et
• al Geographie distnbution of the 20210 G to A prothrombin vanant
Thromb Haemost 1998, 79 706-708
This article is relevant when assessmg etiology of a thrombosis, because parallel
to Factor V Leiden, the 2021 OA prothrombin mutation is very rare to absent in
nonwhite people
18 Kyrie PA, Mannhalter C, Begum S, Stumpften A, Hirschl M, Weltermann A,
et al Clmical studies and thrombin generation m patients homozygous or
heterozygous for the G20210A mutation m the prothrombin gene
Artenoscler Thromb Vase Biol 1 998, 18 1 287-1 291
19 Zawadzki C Gavenaux V, Tnllot N, Bauters A Watel A, Alhenc Gelas M, et
al Homozygous G20210A transition m the prothrombin gene associated
with severe venous thrombotic disease two cases m a French family
Thromb Haemost 1998, 80 1027-1028
20 Alatri A, Franchi F, Moia M Homozygous G20210A prothrombin gene
mutation without thromboembolic events a case report Thromb Haemost
1998 801028-1029
21 Lane DA, Mannucci PM, Bauer KA Bertina RM, Bochkov NP, Boulyjenkov V,
et al Inhented thrombophilia part 2 Thromb Haemost 1996, 76 824-834
22 Martinelli l, Sacchi E, Landi G, Taioli G, Duca F Mannucci PM High nsk of
• cerebral-vem thrombosis in carners of a prothrombin gene mutation and in
users of oral contraceptives N Engl J Med 1998, 338 1 793-1397
In this article, the authors Support evidence of earlier observations that have
demonstrated an interaction between gene (Factor V Leiden of 2021 OA
prothrombin mutation) and environment (oral contraceptives)
23 de Bruijn SFTM, Stam J, Koopman MMW, Vandenbroucke JP Case control
study of nsk of cerebral smus thrombosis m oral contraceptive users who are
carners of hereditary prothrombotic conditions BMJ 1998, 316 589-592
24 Reuner KH Grau A Rickmann H, Stolz E, Juttier E, Druschky KF,
Patscheke H Prothrombin gene G20210 —> A transition is a nsk factor for
cerebral venous thrombosis Stroke 1998, 29 1 765-1 769
25 Eichmger S Mmar E, Hirschl M Bialonczyk C Stam M, Mannhalter C, et
al The nsk of early recurrent venous thromboembolism after oral anticoag
ulant therapy m patients with the G20210A transition m the prothrombin
gene Thromb Haemost 1999, 81 14-17
26 Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, et al A
companson of three moriths of anticoagulation with extended anticoagula
tion for a first episode of idiopathic venous thromboembolism N Engl J
Med 1999,340901-907
27 Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lmdpamtner K,
Hennekens CH Factor V Leiden and risks of recurrent idiopathic venous
thromboembolism Circulation 1997, 92 2800-2802
28 Eichmger S, Pabmger l, Stumpflen A, Hirschl M, Bialonczyk C, Schneider
B, et al The nsk of recurrent venous thromboembolism in patients with
and without Factor V Leiden Thromb Haemost 1997, 77 624-628
29 Ridker PM Long-term, Iow dose warfarm among venous thrombosis
patients with and without Factor V Leiden mutation rationale and design
for the prevention of recurrent venous thromboembolism (PREVEN") tnal
Vase Med 1998,367-73
30 Doggen CJM, Manger Cats V, Bertina RM, Rosendaal FR Interaction of
coagulation defects and cardiovascular nsk factors Increased nsk of
myocardial infarction associated with Factor V Leiden or prothiombm
2021 OA Circulation 1998, 97 1037-1041
31 Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE,
Vos HL A common prothrombin vanant (2021 OA) mcreases the nsk of
myocardial infarction in young women Blood 1997, 90 1747-1750
32 Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE,
Vos HL Factor V Leiden (resistance to protein C) mcreases the nsk of
myocardial infarction m young woman Blood 1997, 89 281 7-2821
33 Cushman M, Rosendaal FR, Psaty BM, Cook EF, Vailliere J, Kuller LH,
Tracy RP Factor V Leiden is not a nsk factor for artenal vascular disease m
the elderly results from the cardiovascular health study Thromb Haemost
1998 79912-915
34 Longstr-eth WT Jr, Rosendaal FR, Siscovick DS, Vos HL, Schwartz SM,
Psaty BM, et al Risk of stroke m young women and two prothrombotic
mutations Factor V Leiden and prothrombin gene vanant (G20210A)
Stroke 1998, 29577-580
35 Koeleman BPC, Reitsma P, Allaart CF, Bertina RM APC resistance äs an
additional nsk factor for thrombosis m protein C-deficient families Blood
1994 84 1031-1035
36 Zoller B Berntsdotter A, Garcia de Frutos P, Dahlback B Resistance to
activated protem C äs an additional factor for thrombosis in protein C defi-
cient families Blood 1995, 85 3518-3523
37 Van Boven HH Reitsma P Rosendaal FR, Bayston TA, Chowdhury V,
Bauer KA, et al Factor V Leiden (FV R506Q) m families with mhented
antithrombm deficiency Thromb Haemost 1996, 75 417-421
38 Ehrenfort S, Ludwig G, Klinke S, Krause M, Scharrer l, Nowak Goettl U
The prothrombin 20210 A allele is frequently combmed in young carners of
the Factor V Arg 506 to Gin mutation with venous thrombophilia Blood
1998,91 2209-2210
39 Zoller B, Svensson PJ, Dahlback B, Hillarp A The A20210 allele of the
prothrombin gene is frequently associated with the Factor V Arg 506 to
Gin mutation but not with protein S deficiency m thrombophilic families
Blood 1998,91 2210-2211
40 Alhenc Gelas M, Le Cam-Duchez V, Emmerich J, Frebourg T, Fiessinger Jn,
Borg JY, Aiach M The A20210 allele of the prothrombin gene is not
frequently associated with the Factor V Arg 506 to Gin mutation m throm
bophilic patients Blood 1997, 90 1 711
41 Den Heijer M, Rosendaal FR Blom HJ, Gerrits WBJ, Bös GMJ Hyper
• homocysteinemia and venous thrombosis a meta analysis Thromb Haemost
1998,80 874-877
In this article, the authors give a nice state of-the art overview of homocysteine
mia and venous thrombosis durmg 1998
42 Frosst P, Blom H, Milos R, Goyette P, Sheppard CA, Matthews RG, et al
A candidate genetic nsk factor for vascular disease a common mutation m
methylenetetrahydrofolate reductase Nature Genet 1995, 10111-113
43 Kluijtmans LAJ, den Heijer M, Reitsma PH, Heil S, Blom HJ, Rosendaal FR
Thermolabile methylenetetrahydrofolate reductase and Factor V Leiden m
the nsk of deep vem thrombosis Thromb Haemost 1998, 79 254-258
44 Brown K, Luddington R Baglm T Effect of the MTHFRC677T vanant on
nsk of venous thromboembolism interaction with Factor V Leiden and
prothrombin (F2G20210A) mutations Br J Haematol 1998, 103 42-44
45 Margaglione M D'Andrea G, d'Addedda M, Giuliam N Cappucci G,
lannaccone L, et al The methylenetetrahydrofolate reductase TT677 geno-
type is associated with venous thrombosis mdependently of the coexis-
Thrombophilia Huisman and Rosendaal 297
tence of the FV Leiden and the prothrornbin 2021 OA mutation. Thromb 47 Den Heijer M, Koster T, Blom HJ, Bös GMJ, Briet E, Reitsma PH, et al.:
Haemost 1998, 79:907-911. Hyperhomocysteinemia äs a risk factor for deep-vem thrombosis. N Engl J
Med 1996,334:759-762.
46 Ridker PM, Hennekens Ch, Seihub J, Miletich JP, Malinow R, Stampfer M:
Interrelation of hyperhomocysteinemia, Factor V Leiden and the risk of 48 Rosendaal FR: Venous thrombosis: a multicausal disease. Lancet 1999,
future venous thromboembolism. Circulation 1997, 95:1 777-1 782. 353:11 76-11 73.
